Deals channel feed – Endpoints News

Deals channel feed

PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

Last month

GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

Last month

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Last month

F-star management takes company private, two years after $161M cash exit to Sino's invoX

Last month

Tang Capital's Concentra nabs a win, making a deal to buy Allakos

Last month

New CDMO emerges, acquires cell and gene manufacturer Landmark Bio

Last month

Bluebird gets new M&A bid, seeking to top private equity offer

Last month

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Last month

Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrin

Last month

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Last month

Why Miga Health's co-founders decided to quit building

Last month

Aurion CEO is out as Alcon takes majority stake in cell therapy startup

Last month

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

Last month

Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui

Last month

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot

Last month

The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued

Last month

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

Last month

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

Last month

Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter

Last month

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Last month

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Last month

AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs

Last month

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Last month

AstraZeneca to buy cell therapy startup for $425M upfront

Last month

First page Previous page 123 4 5 Next page Last page